Avidity Biosciences (RNA) Competitors $32.69 +0.04 (+0.12%) Closing price 04:00 PM EasternExtended Trading$34.00 +1.31 (+4.00%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA vs. ITCI, GMAB, RDY, MRNA, ASND, VTRS, QGEN, ROIV, RVMD, and LNTHShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), Revolution Medicines (RVMD), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Ascendis Pharma A/S Viatris Qiagen Roivant Sciences Revolution Medicines Lantheus Avidity Biosciences (NASDAQ:RNA) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation. Does the MarketBeat Community believe in RNA or ITCI? Intra-Cellular Therapies received 354 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 69.14% of users gave Avidity Biosciences an outperform vote while only 65.99% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformAvidity BiosciencesOutperform Votes16869.14% Underperform Votes7530.86% Intra-Cellular TherapiesOutperform Votes52265.99% Underperform Votes26934.01% Is RNA or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Avidity Biosciences' net margin of -2,772.45%. Intra-Cellular Therapies' return on equity of -9.93% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Avidity Biosciences-2,772.45% -27.66% -24.56% Intra-Cellular Therapies -14.07%-9.93%-8.38% Which has stronger valuation & earnings, RNA or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Avidity Biosciences. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvidity Biosciences$10.90M354.94-$212.22M-$2.89-11.13Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Does the media favor RNA or ITCI? In the previous week, Avidity Biosciences had 8 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 10 mentions for Avidity Biosciences and 2 mentions for Intra-Cellular Therapies. Avidity Biosciences' average media sentiment score of 1.67 beat Intra-Cellular Therapies' score of 0.00 indicating that Avidity Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avidity Biosciences 9 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Intra-Cellular Therapies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in RNA or ITCI? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 3.7% of Avidity Biosciences shares are held by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, RNA or ITCI? Avidity Biosciences has a beta of 1.01, meaning that its stock price is 1% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Do analysts rate RNA or ITCI? Avidity Biosciences presently has a consensus target price of $66.69, suggesting a potential upside of 107.28%. Intra-Cellular Therapies has a consensus target price of $109.70, suggesting a potential downside of 16.81%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Avidity Biosciences is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 SummaryAvidity Biosciences beats Intra-Cellular Therapies on 10 of the 18 factors compared between the two stocks. Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.86B$6.72B$5.49B$7.94BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-11.157.3722.5818.55Price / Sales354.94242.94397.25103.00Price / CashN/A65.8538.1834.62Price / Book4.766.486.704.26Net Income-$212.22M$143.68M$3.23B$248.39M7 Day Performance4.03%1.79%1.26%1.27%1 Month Performance20.33%6.68%3.75%3.85%1 Year Performance24.71%-2.73%15.78%5.23% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences2.8518 of 5 stars$32.69+0.1%$66.69+104.0%+35.3%$3.93B$10.90M-11.35190Upcoming EarningsPositive NewsITCIIntra-Cellular Therapies0.8793 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4448 of 5 stars$20.63+0.2%$39.17+89.9%-23.6%$13.66B$21.53B11.861,660Upcoming EarningsAnalyst RevisionRDYDr. Reddy's Laboratories1.8404 of 5 stars$13.95+1.2%$17.00+21.9%-5.3%$11.65B$311.31B22.2124,800Upcoming EarningsPositive NewsMRNAModerna4.4332 of 5 stars$27.46+0.9%$58.70+113.8%-74.1%$10.62B$3.20B-2.963,900Earnings ReportNews CoverageGap DownASNDAscendis Pharma A/S2.3124 of 5 stars$164.88+0.4%$204.67+24.1%+23.1%$10.05B$363.64M-23.22640Earnings ReportNews CoveragePositive NewsVTRSViatris1.8326 of 5 stars$8.25+1.5%$10.50+27.3%-27.2%$9.85B$14.74B-11.1537,000Upcoming EarningsQGENQiagen3.6881 of 5 stars$42.49+1.0%$47.83+12.6%+4.0%$9.45B$1.98B118.316,030Upcoming EarningsAnalyst RevisionROIVRoivant Sciences2.2019 of 5 stars$11.19+1.6%$17.50+56.4%+6.6%$7.98B$122.59M-74.60860RVMDRevolution Medicines3.766 of 5 stars$41.47+7.0%$66.67+60.8%+8.3%$7.71B$742,000.00-11.55250Upcoming EarningsAnalyst ForecastPositive NewsLNTHLantheus3.9712 of 5 stars$102.70+0.9%$129.43+26.0%+56.8%$7.03B$1.53B17.09700Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Ascendis Pharma A/S Competitors Viatris Competitors Qiagen Competitors Roivant Sciences Competitors Revolution Medicines Competitors Lantheus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
